Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST)

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

In Fabry disease, progressive glycolipid accumulation leads to damage in kidney and other organs. This study was designed to determine the prevalence rate of Fabry disease in Japanese dialysis patients.

Methods

All dialysis patients agreeing to Japan Fabry disease screening study (J-FAST) with informed consent were selected except for Fabry disease. The screening was performed by a method of measuring plasma and/or leukocytes lysosomal α-galactosidase A protein level and α-galactosidase A activity. If positive, genetic analysis was carried out upon patient’s agreement.

Results

J-FAST dealt with 8547 patients (male 5408, female 3139). At the tertiary examination, 26 out of 8547 patients were found to be positive. Six out of 26 patients could not accept genetic analysis because of death. Remaining 20 patients agreed with genetic analysis; then 2 patients (male 2, female 0) had a variation of the α-Gal gene and 11 patients showed E66Q variations. Therefore, the frequency of Fabry disease in J-FAST was 0.04 % (2/5408) in males and 0 % (0/3139) in females, and then 0.02 % (2/8547) in all patients. The presumptive clinical diagnoses of end-stage kidney disease (ESKD) were 10 chronic glomerulonephritis, 7 diabetic nephropathy, 3 unknown etiology, 3 nephrosclerosis, 1 gouty nephropathy, 1 autosomal dominant polycystic kidney disease and 1 renal tuberculosis among 26 tertiary positive patients. Two male Fabry patients were initially diagnosed as nephrosclerosis and chronic glomerulonephritis.

Conclusions

The prevalence rate of Fabry disease in J-FAST was 0.02 %. Moreover, Fabry disease could not be ruled out as the clinical diagnosis of ESKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kint JA. Fabry’s disease: alpha-galactosidase deficiency. Science. 1970;167(3922):1268–9.

    Article  CAS  PubMed  Google Scholar 

  2. De Francesco PN, Mucci JM, Ceci R, et al. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab. 2013;109:93–9.

    Article  PubMed  Google Scholar 

  3. Grünfeld JP, Lidove O, Joly D, Barbey F. Renal disease in Fabry patients. J Inherit Metab Dis. 2001;24(Suppl 2):71–4.

    Article  PubMed  Google Scholar 

  4. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transpl. 2009;24:2102–11.

    Article  Google Scholar 

  5. Waldek S, Germain DP, Wanner C, Warnock DG. Enzyme replacement therapy for Fabry’s disease. Lancet. 2010;375(9725):1523.

    Article  PubMed  Google Scholar 

  6. Kodama C, Nakao M, Takenaka T. Is Fabry disease a rare disease? On screening of Fabry disease in chronic dialysis male patients and its clinical feature. The report of idiopathic cardiomyopathy The Ministry of Health and Welfare, 1995; 41–4.

  7. Utsumi K, Kase R, Takata T, et al. Fabry disease in patients receiving maintenance dialysis. Clin Exp Nephrol. 2000;4:49–51.

    Article  Google Scholar 

  8. Spada M, Pagliardini S. Screening for Fabry disease in end-stage nephropathies. J Inherit Metab Dis. 2002;25(Suppl 1):113.

    Google Scholar 

  9. Linthorst GE, Hollak CE, Korevaar JC, et al. Alpha-Galactosidase a deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transpl. 2003;18:1581–4.

    Article  CAS  Google Scholar 

  10. Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64:801–7.

    Article  PubMed  Google Scholar 

  11. Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004;15:1323–9.

    Article  CAS  PubMed  Google Scholar 

  12. Tanaka M, Ohashi T, Kobayashi M, et al. Identification of Fabry’s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol. 2005;64:281–7.

    Article  CAS  PubMed  Google Scholar 

  13. Bekri S, Enica A, Ghafari T, et al. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract. 2005;101:c33–8.

    Article  PubMed  Google Scholar 

  14. Ichinose M, Nakayama M, Ohashi T, et al. Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol. 2005;9:228–32.

    Article  CAS  PubMed  Google Scholar 

  15. Merta M, Reiterova J, Ledvinova J, et al. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transpl. 2007;22:179–86.

    Article  Google Scholar 

  16. Porsch DB, Nunes AC, Milani V, et al. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report. Ren Fail. 2008;30:825–30.

    Article  PubMed  Google Scholar 

  17. Fujii H, Kono K, Goto S, et al. Prevalence and cardiovascular features of Japanese hemodialysis patients with Fabry disease. Am J Nephrol. 2009;30:527–35.

    Article  PubMed  Google Scholar 

  18. Terryn W, Poppe B, Wuyts B, et al. Two-tier approach for the detection of alpha-galactosidase a deficiency in a predominantly female haemodialysis population. Nephrol Dial Transpl. 2008;23:294–300.

    Article  CAS  Google Scholar 

  19. Gaspar P, Herrera J, Rodrigues D, et al. Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet. 2010;11:19.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Nishino T, Obata Y, Furusu A, et al. Identification of a novel mutation and prevalence study for Fabry disease in Japanese dialysis patients. Ren Fail. 2012;34:566–70.

    Article  CAS  PubMed  Google Scholar 

  21. Doi K, Noiri E, Ishizu T, et al. High-throughput screening identified disease-causing mutants and functional variants of α-galactosidase A gene in Japanese male hemodialysis patients. J Hum Genet. 2012;57:575–9.

    Article  CAS  PubMed  Google Scholar 

  22. Kikumoto Y, Sugiyama H, Morinaga H, et al. The frequency of Fabry disease with the E66Q variant in the α-galactosidase A gene in Japanese dialysis patients: a case report and a literature review. Clin Nephrol. 2012;78:224–9.

    Article  CAS  PubMed  Google Scholar 

  23. Maruyama H, Takata T, Tsubata Y, et al. Screening of male dialysis patients for Fabry disease by plasma globotriaosylsphingosine. Clin J Am Soc Nephrol. 2013;8:629–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Nakai S, Iseki K, Itami N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2009). Ther Apher Dial. 2012;16:11–53.

    Article  PubMed  Google Scholar 

  25. Kitagawa T, Suzuki K, Ishige N, et al. Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr Nepherol. 2008;23(9):1461–71.

    Article  Google Scholar 

  26. Desnick RJ, Allen KY, Desnick SJ, et al. Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine and leukocytes. J Lab Clin Med. 1973;81:157–71.

    CAS  PubMed  Google Scholar 

  27. Mayes JS, Scheerer JB, Sifers RN, et al. Differential assay for lysosomal α-galactosidase in human tissues and its application to Fabry’s disease. Clin Chim Acta. 1981;112:247–51.

    Article  CAS  PubMed  Google Scholar 

  28. Kobayashi M, Ohashi T, Fukuda T, et al. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene. Mol Genet Metab. 2012;107:711–5.

    Article  CAS  PubMed  Google Scholar 

  29. Lee BH, Heo SH, Kim GH, et al. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet. 2010;55:512–7.

    Article  CAS  PubMed  Google Scholar 

  30. Inoue T, Hattori K, Ihara K, et al. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet. 2013;58:548–52.

    Article  CAS  PubMed  Google Scholar 

  31. Tuttolomondo A, Pecoraro R, Simonetta I, et al. Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des. 2013;19(33):5974–96.

    Article  CAS  PubMed  Google Scholar 

  32. Brady RO, Tallman JF, Johnson WG, et al. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry’s disease. N Engl J Med. 1973;289:9–14.

    Article  CAS  PubMed  Google Scholar 

  33. Desnick RJ, Dean KJ, Grabowski G, et al. Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase a isozymes. Proc Natl Acad Sci USA. 1979;76:5326–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Weidemann F, Niemann M, Störk S, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Smid BE, Rombach SM, Aerts JM, et al. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis. 2011;6:69.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Desnick RJ. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase a orphan products and one FDA approval. Expert Opin Biol Ther. 2004;4:1167–76.

    Article  CAS  PubMed  Google Scholar 

  37. Demontis R. Diagnosis of Fabry disease: usefulness of the clinical investigation. Rev Med Intern. 2010;31(Suppl 2):S229–32.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to our sincere thank for their efforts of conducting J-FAST in various areas of JAPAN to the members of local committee listed below. In addition, we also express of our thanks to all the doctors and staff members of cooperative clinics for performing J-FAST. Dr Ichiei Narita, Niigata University Graduate School of Medical and Dental Sciences. Dr Kazutaka Kukita, Sapporo Hokuyu Hospital. Dr Yoshio Taguma, Sendai Shakaihoken Hospital. Dr Kaoru Tabei, Saitama Medical Center, Jichi Medical University. Dr Shigeko Hara, Toranomon Hospital. Dr Tadao Akizawa, Showa University School of Medicine. Dr Seiichi Matsuo, Nagoya University School of Medicine. Dr Yukio Yuzawa, Fujita Health University School of Medicine. Dr Yoshiharu Tsubakihara, Osaka General Medical Center. Dr Hirofumi Makino, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. Dr Hitoshi Sugiyama, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. Dr Noriaki Yorioka, Hiroshima Kidney Organization. Dr Takahito Nasu, Tokuyama Central Hospital. Dr Kumio Tomita, Graduate School of Faculty of Life Science, Kumamoto University. Dr Kunitoshi Iseki, University Hospital of the Ryukyu.

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan

    Osamu Saito & Tetsu Akimoto

  2. Division of Nephrology, Department of Medicine, Japan Community Health Care Organization Utsunomiya Hospital, Minamitakasago-cho 11-17, Tochigi, 321-0143, Japan

    Eiji Kusano

  3. Department of Medicine, Koga Red Cross Hospital, Ibaraki, Japan

    Yasushi Asano

  4. Tokyo Health Service Association, Tokyo, Japan

    Teruo Kitagawa, Ken Suzuki & Nobuyuki Ishige

  5. Department of Blood Purification, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan

    Takashi Akiba

  6. Yokohama Dai-ichi Hospital, Kanagawa, Japan

    Akira Saito

  7. Department of Nephrology, Osaka City University Graduate School of Medicine, Osaka, Japan

    Eiji Ishimura

  8. Department of Pediatric Nephrology, Tokyo Women’s Medical University, School of Medicine, Tokyo, Japan

    Motoshi Hattori

  9. Yaizu City Hospital, Shizuoka, Japan

    Akira Hishida

  10. Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

    Chu Guili & Hiroki Maruyama

  11. Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan

    Masahisa Kobayashi

  12. Department of Pediatrics, Institute for DNA Medicine, The Jikei University School of Medicine, Tokyo, Japan

    Touya Ohashi

  13. Health Sciences University of Hokkaido, Hokkaido, Japan

    Ichiro Matsuda

  14. Department of Genetics and Genome Science, The Jikei University School of Medicine, Tokyo, Japan

    Yoshikatsu Eto

Authors
  1. Osamu Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eiji Kusano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsu Akimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasushi Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Teruo Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ken Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobuyuki Ishige
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takashi Akiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akira Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eiji Ishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Motoshi Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Akira Hishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Chu Guili
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hiroki Maruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Masahisa Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Touya Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Ichiro Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Yoshikatsu Eto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eiji Kusano.

Ethics declarations

Conflict of interest

The authors have declared that no conflict of interest exists.

Sources of support

Kidney Foundation, Japan.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saito, O., Kusano, E., Akimoto, T. et al. Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST). Clin Exp Nephrol 20, 284–293 (2016). https://doi.org/10.1007/s10157-015-1146-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-015-1146-7

Keywords

Search

Navigation